<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" >
   <HEAD>
	<TITLE>Human Inosine Monophosphate Dehydrogenase 2 enzyme - active IMPDH 2 enzyme </TITLE>
	<!--[if IE 6]><meta http-equiv="Refresh" content="0; url=http://www.novocib.com/IE7/index.html"><![endif]-->
    <!--[if IE 7]><meta http-equiv="Refresh" content="0; url=http://www.novocib.com/IE7/index.html"><![endif]-->
    <META http-equiv=Content-Type content="text/html; charset=iso-8859-1">
	<META name=Title content="Purine Metabolism Enzymes - Nucleoside Metabolism Enzymes - Nucleotide Metabolism Enzymes">
	<META name=Author content="NovoCIB (lbalakireva@novocib.com)">
	<META name=Subject content=">
	<META name=Description content="NOVOCIB's IMPDH 2 is active enzyme characterized for its affinity for substrates and sensitivity to enzyme inhibitors mycophenolic acid and ribavirine-monophosphate.">
	<META name=Keywords content="buy IMPDH, human IMPDH, E.C.1.1.1.205, Inosine Monophosphate Dehydrogenase, recombinant IMPDH, IMP dehydrogenase, GTP biosynthesis, inosine 5'-monophosphate dehydrogenase, mycophenolic acid, ribavirin, validated target, immunosuppression"> 
	<META content=en name=Language>
	<META content=" name=Expires>
	<META content="NOVOCIB © 2006" name=Distribution>
	<META content=All name=Robots>
	   <!-- css -->
	   <LINK href="css/Stylesmaller.css" type=text/css rel=stylesheet>
	   <!-- favico -->
	   <LINK href="http://www.novocib.com/favicon.ico" rel="shortcut icon">
	   <link rel="stylesheet" media="screen" type="text/css" title="Style" href="css/Stylesmaller.css">
<!-- end favico -->

<!-- script du menu -->
<script type="text/javascript" src="JavMenu.js"></script>
 <!-- détéction du navigateur -->
<script type="text/javascript" src="navdetecteur.js"></script>

<!-- important pour que les vieux navigateurs ne comprennent pas le CSS -->
<style type="text/css">
    @import "Stylesmaller.css";
</style>

</head>
<body>
<div id="page">

<!--[if lt IE 8]><div align=left class="smallRed">This site is designed for IE 8 or IE 9. We are working for compatibility with lower versions. For better convenience, please visit us with IE 8, IE 9, Google Chrome or Firefox, or any other compatible navigator</div><![endif]-->

<!-- HEADER -->
<div id="header">
  <div id="headerLogo"><a href="http://www.novocib.com" title="NovoCIB Home Page"><img src="images/logo NovoCIB1.png" width="247" height="122"/></a></div>
    <p>&nbsp;
     </script>
<script src="//platform.linkedin.com/in.js" type="text/javascript">
 lang: en_US
</script>
<script type="IN/FollowCompany" data-id="5048147" data-counter="none"></script>
    <div id="headerSlogan"><SPAN class=ChapterThirdTitle><em>Reliable solutions for nucleotide assessment</em></SPAN><img src="images/HorizBarMenu.gif" width=380 /></div>
    <div><a href="http://www.novocib.com/contact" class=MenuContact title="Contact">Contact</a>&nbsp;&nbsp;</div> <br /><br />
</div>
<!-- End HEADER -->

<!-- SQUARE RIGHT -->
<div id="SquareRight" class="small">
  
  <div align="center" class=ChapterThirdTitle style4>Award</div>
  <div align=center>Dr Larissa Balakireva, CEO &amp; Founder of NovoCIB, was awarded with the Trophy of
      <br /><a href="http://www.aufeminin.com/evenement/femmes-en-or/" Title="Femmes en Or 2011" class="boldRedAct" target=_blank>"Femmes en Or 2011, Femme de l'Innovation"</a>
      <br />in September 2011
  </div>.
  <div align=center><a href="http://www.aufeminin.com/evenement/femmes-en-or/" Title="Femmes en Or 2011" class="boldRedAct" target=_blank><img src="images/trophees femmes en or.jpg"/ width=100 ></a>
  </div>
  
    
</div>
<!-- End SQUARE RIGHT -->



<!-- MENU PRINCIPAL, HORIZONTAL -->
<div id="menu">
  <ul id="MenuDeroul">
    <li><a href="Purified_Active_Enzymes.html"><strong>PURIFIED<br />
    ENZYMES</strong></a>
        <ul>
            <li><a href="Recombinant_Purine_Metabolism_Enzymes.html">Purine Metabolism Enzymes</a>
                <ul>
                    <li><a href="IMPDH_Recombinant_Enzyme.html">IMPDH Enzymes<br /><span class="ItemNameHoriz">Inosine Monophosphate Dehydrogenase</span></a>
                        <ul>
                            <li><a href="Human_Recombinant_IMPDH.html">Human IMPDH</a></li>
                            <li><a href="Bacterial_Recombinant_IMPDH.html">Bacterial IMPDH</a></li>
                        </ul>
                    </li>
                    <li><a href="Human_Recombinant_PNP.html">PNP Enzyme<br /><span class=ItemNameHoriz>Purine Nucleoside Phosphorylase</span></a></li>
                     <li><a href="Xanthine_Dehydrogenase_XDH.html">XDH Enzyme<br /><span class=ItemNameHoriz>Xanthine dehydrogenase</span></a></li>
                    <li><a href="Human_Recombinant_HGPRT.html">HGPRT Enzyme<br /><span class=ItemNameHoriz>Hypoxanthine-guanine phosphoribosyltransferase</span></a></li>
                </ul>
            </li>
            <li><a href="Recombinant_Nucleoside_Kinases.html">Nucleoside Kinase  Nucleotidase</a>
                <ul>
                    <li><a href="Recombinant_Adenosine_Kinase.html">ADK Enzyme<br /><span class=ItemNameHoriz>Adenosine Kinase</span></a></li>
                    <li><a href="Recombinant_Deoxycytidine_Kinase.html">dCK Enzyme<br /><span class=ItemNameHoriz>Deoxycytidine Kinase</span></a></li>
                    <li><a href="Recombinant_UMP-CMP_Kinase.html">CMK Enzyme<br /><span class=ItemNameHoriz>UMP-CMP Kinase</span></a></li>
                    <li><a href="Recombinant_5'-nucleotidase.html">cN-II Enzyme<br /><span class=ItemNameHoriz>cytosolic 5'-nucleotidase II</span></a>            </li>
                </ul>
            </li>
            <li><a href="Bacterial_Bioluminescence_Enzymes.html">Bacterial Bioluminescence Enzymes</a>
                <ul>
                    <li><a href="Bacterial_Luciferase.html">Bacterial Luciferase, Highly Pure<br /><span class="ItemNameHoriz">from <em>Photobacterium phosphoreum</em></span></a></li>
                    <li><a href="Bacterial_FMN_Reductase.html">FMN Reductase<br /><span class="ItemNameHoriz">for Bacterial Bioluminescence</span></a>            </li>
                </ul>
            </li>
      </ul>
    </li>
    <li><a href="Nucleotides_Life_Science.html"><strong>NUCLEOTIDES<br /> 
      LIFE SCIENCE<br />
    </strong></a>	
        <ul>
          <li><a href="Convenient_Assay_Kits.html">Assay Kits</a>
          <li><a href="Cellular_Nucleotides_Analysis.html">HPLC Analysis</a>
  </ul>
   <li><a href="Freshness_Assay_Kits.html"><strong>NUCLEOTIDES<br />
      FRESHNESS</strong></a>
       <ul>
              <li><a href="Freshness_Principle.html">Kit Principle</a>
             <li><a href="Freshness_Protocol.html">How It Works</a>
             <li><a href="Case_Studies.html">Case Studies</a>
            <ul><li><a href="Fish_Freshness.html">Fish</a>
             <li><a href="Meat_Freshness.html">Meat</a>    
              </ul></li></ul>
    </li>
    <li><a href="Nucleotide_Analysis_Services.html"><strong>DIETARY<br />
      NUCLEOTIDES</strong></a>
      <ul> 
           
             <li><a href="Yeast_Extract_Nucleotide_Analysis.html">Yeast Extract</a></li>
            <li><a href="Infant_Formula_Nucleotide_Analysis.html">Infant Formula</a></li>
            <li><a href="Aquaculture_Nucleotide_Analysis.html">Aquaculture Feed</a></li>
             <li><a href="Feed_Nucleotide_Analysis.html">Feed &amp; Pet Food</a></li>
            <li><a href="By-Products_Nucleotides.html">By-Products Valorisation</a></li> 
            </ul>
      </li>
     <li><a href="ATP_Breakdown_Assay_Kit.html"><strong>SLAUGHTER<br />
      NUCLEOTIDES<br />
    </strong></a>	
        <ul>
        <li><a href="ATP_breakdown_salmon.html">Fish </a></li>
        <li><a href="ATP_breakdown_meat.html">Meat</a></li>
        </ul>
    </li>
  </ul>

</div>

<!-- End MENU PRINCIPAL, HORIZONTAL -->




<!-- Sub Menu, Vertical -->
<!-- End Sub Menu, Vertical -->

<br />


<!-- page content -->
   
<div id="content" class="default">
  
  <div align="justify"> 
    <!-- Intro -->
    <table width=640>
        <tr><td><table width="200" id="ProductPicture">
                    <tr><td colspan=2 align=center class="zoomWidthW350-450"><p><img src="images/IMPDH reaction.png" width=391 height="74"/><br />
                    <p><span class="big14bold"><span class="ChapterThirdTitle">Human  IMPDH 2</span></span><br />
<span class="big14bold">Ref. #E-Nov1</span><br />
                        </p></td>
              </tr>
                    <tr><td align=left><strong>Quantity</strong>
                        </td>
                        <td align=right><strong>Price*</strong>
                        </td>
                    </tr>
                    <tr>
                      <td align=left><strong>50 mU</strong></td>
                        <td align=right><strong>&euro; 305.00</strong>
                        </td>
                    </tr>
                    <tr>
                      <td align=left><strong>100 mU</strong>
                      </td>
                        <td align=right><strong>&euro; 495.00</strong>
                        </td>
                    </tr>
                    <tr>
                      <td align=left><strong>250 mU</strong>
                      </td>
                        <td align=right><strong>&euro; 1220.00</strong>
                        </td>
                    </tr>
                    <tr>
        <td colspan=2><p><span class="small">* Pricing updated December 8<sup>th</sup>, 2013</span>        
          <p>Provided in stable lyophilized form and <span class="defaultBlue"><strong>shipped without dry ice</strong></span><br />
              <strong>To buy human IMPDH 2 enzyme <a href="mailto:contact@novocib.com?subject=Human%20IMPDH%20Enzyme%20Order" class="boldRedAct" title="IMPDH II Enzyme Order">click here</a> or ask for</strong> <a href="mailto:contact@novocib.com?subject=Human%20IMPDH%20II%20Enzyme%20Quotation%20Request" class="TabServRed" title="Human IMPDH II quotation">Quotation</a></td>
              </table>
               <p align="left"><span align=right class="ChapterThirdTitle">Human  IMPDH, Type 2</span><br />
                <br />
                <p><span class="smallbold">Synonyms:</span>  inosine 5'-monophosphate dehydrogenase, type 2, IMP dehydrogenase, type II, IMPDH2
                <p>
                Inosine 5'-monophosphate dehydrogenase type 2 (IMPDH 2, E.C.1.1.1.205) is the predominant isoform of IMPDH and a validated target to treat a wide range of cancers and infectious diseases and to prevent lymphocytes proliferation.<br /><br />
                <strong> NOVO</strong><span class="boldRed">CIB</span>'s IMPDH 2 has been cloned by RT-PCR amplification of mRNA extracted from human hepatoma cells (NP_000875.2, 100% identity) and expressed in <em>E.coli</em>. <br /><br />
                <strong>NOVO</strong><span class="boldRed">CIB</span>'s purified IMPDH 2 is an active enzyme characterized for its affinity for inosine 5'-monophosphate  and NAD substrates, and its sensitivity to enzyme inhibitors such as mycophenolic acid and ribavirine-monophosphate.</p>
                <p>  <strong>Unit Definition:</strong> One unit of IMPDH Type II catalyzes the oxydation of 1 µmole of IMP to XMP per minute at pH 8.8 at 37 °C
                       <br />
                   
            <p><strong>Specific Activity:</strong> &ge; 0.050 unit/mg protein.<br />
            </tr>
        <tr><td colspan=2>
            </td>
        </tr>
    </table>
    <br />
    <!-- End Intro -->
  </div>
  
  <br />
  
  <div  id="PrincipalItem">  
    <!-- Human Recombinant IMPDH II - Product description -->
    <br />
      <div class=default>
<table cellspacing=10 class=medium align=justify>
               <tr valign=top>
                   <td><div class="FloatLeft"><img src="images/IMPDH Gel.png" height=160/></div>
                     <p><br />
                       <br />
                       <br />
                   </p>
                 </td>
                   <td><strong>Assay condition:</strong> KH<sub>2</sub>PO<sub>4</sub> 0.1M, pH8.8, NAD 250µM, DTT 2.5mM, 2.5mU/ml of human recombinant IMPDH II, Incubation at 37°C. Reaction started by adding IMP at 250&micro;M final concentration. NADH formation was followed in an iEMS Reader MF (Labsystems)  plate reader at 340nm.
                 <div align=center><img src="images/IMPDH IC50.png" width=374 height="240"/>                 </div></td>
             </tr>
           </table>
           <div align=right class=medium><strong>Download this document</strong>&nbsp;<a href="images/NovoCIB E-Nov1.pdf" target=_blank class="mediumboldRedAct" title="NovoCIB's Human IMPDH">"NovoCIB's Human Recombinant IMPDH"&nbsp;<img width=20 src="images/pdficon_large.gif" /></a>           </div>
        <div></div>
           <div align=right class="mediumbold">See also our brochure <a href="images/NovoCIB IMPDH Services.pdf" target=_blank class="mediumboldRedAct" title="NovoCIB IMPDH Products & Services">"NovoCIB IMPDH Products & Services"&nbsp;<img width=20 src="images/pdficon_large.gif" /></a>
           </div>
      </div>
    </p>
    <!-- End Human Recombinant IMPDH II - Product description -->
  </div>
  
  <br />
  <div id="PrincipalItem">
    <!-- IMPDH, a choice target for major therapeutic applications -->
    <p><a name="IMPDH, a choice target for major therapeutic applications" class="ChapterThirdTitle">IMPDH - a choice target for major therapeutic applications</a>
       <div align=Right><a href="#top" class="ReturnToTop">(^Top)</a></div>
       <div></div>
       <div class="small"><span class="smallbold">Synonyms:</span> inosine 5'-monophosphate dehydrogenase, IMP dehydrogenase
       </div>
       <br>
       <div class=default><strong>Catalytic activity</strong>
           <br />Inosine Monophosphate Dehydrogenase (IMPDH) converts inosine 5’-monophosphate (IMP) to xanthosine 5’- monophosphate (XMP) using NAD<sup>+</sup> as a cofactor.
           <div align=center><img src="images/IMPDH reaction.png" width=400/></div>
           The oxidation of IMP to XMP is considered as the pivotal step in the biosynthesis of guanine nucleotide, whose pool controls cell proliferation and many other major cellular processes<span class=medium><sup>(1)</sup></span>. The decrease in guanine nucleotide resulting from IMPDH inhibition interrupts the nucleic acid synthesis in proliferating cells. The involvement of IMPDH in <em>de novo</em> guanine nucleotide biosynthesis makes IMPDH a crucial enzyme in cell proliferation and differentiation<span class=medium><sup>(2)</sup></span>. IMPDH is recognized as a validated target for several major therapeutic areas. IMPDH inhibitors are exploited as antiviral (<em>e.g.</em> ribavirine), antiparasitic, antimicrobial, antileukemic, and immunosuppressive agents<span class=medium><sup>(2)</sup></span>. IMPDH Type II is the predominant isoform of the enzyme and is selectively expressed in proliferating cells, including lymphocytes and tumor cells<span class=medium><sup>(2)</sup></span>.
           <br />
           <p><sup></sup><strong>IMPDH in immunology</strong>
           <br />
           IMPDH is highly active in lymphocytes. It is a validated target to treat immunological diseases and to induce immunosuppression (CellCept<sup>&reg;</sup>, a mycophenolic acid (MPA) prodrug - Roche – CHF1.85 Bn as an immunosuppressive agent in 2006, orphan drug designation in 2006 for Myasthenia Gravis; CellCept<sup>&reg;</sup> reached positive results in Phase III trials in Lupus Nephritis). IMPDH is also recognized as an excellent target for the treatment of psoriasis, rheumatoid arthritis (RA), and systemic lupus erythematosus (SLE)<span class=medium><sup>(3)</sup></span>.
           <br />
           <p><sup></sup><strong>IMPDH in oncology</strong>
           <br />
           IMPDH, and particularly Type II, which is overexpressed in tumor cells, is considered as a highly potent target for cancer chemotherapy<span class=medium><sup>(1, 2, 4, 5)</sup></span>. Several IMPDH inhibitors are under development for the treatment of Acute and Chronic Myelogenous Leukemia (AML, CML)<span class=medium><sup>(6)</sup></span>, and other cancers (pancreas, colon, bladder…). Additionally, it has been shown that the use of IMPDH inhibitors counteracts the drug resistance<span class=medium><sup>(7)</sup></span> that may appear in certain tumors. For instance, methotrexate resistance is directly related to the overexpression of IMPDH, whose inhibition restores the drug efficacy<span class=medium><sup>(8)</sup></span>. Combination with other anti-cancer drugs extends the potential application of IMPDH inhibitors.
           <br />
           <p><sup></sup><strong>Current development of IMPDH inhibitors</strong>
           <br />
           CellCept<sup>&reg;</sup>, ribavirin, mizoribine, and tiazofurine are examples of currently used drugs that target IMPDH. Benzamide riboside, tiazofurine, and MPA are under development in Phase II/III in leukemia: results are judged very encouraging<span class=medium><sup>(8)</sup></span>.
           <br />The IMPDH II atomic structure has been resolved and it provides a valuable background for further leads optimization<span class=medium><sup>(9)</sup></span>. Besides nucleosides analogues, NCEs have been identified as IMPDH inhibitors<span class=medium><sup>(10, 11, 12, 13, 14)</sup></span> and enter development trials (<em>e.g.</em> AVN-944: Phase I in advanced hematologic malignancies, Phase II in pancreatic and other solid tumors).
           <br />All this demonstrates how promising new IMPDH inhibitors could be and why the inhibiting activity of compounds is worth being evaluated on such a highly pertinent target.
           <br />
           <!-- Compounds Table -->
           <table align=center cellspacing=5>
               <tr align=center>
                   <td valign=top>AVN-944<img src="images/AVN-944.png" width=200 /></td>
                   <td valign=top>VX-148<img src="images/VX-148.png" width=200 /></td>
                   <td valign=top>VX-497<img src="images/VX-497.png" width=200 /></td>
               </tr>
               <tr align=center>
                   <td valign=top>MPA (mycophenolic acid)<img src="images/MPA.png" width=150 /></td>
                   <td valign=top>CellCept<sup>&reg;</sup><img src="images/MMF.png" width=200 /></td>
                   <td valign=top>BMS-337197<img src="images/BMS-337197.png" width=150 /></td>
               </tr>
               <tr align=center>
                   <td valign=top></td>
                   <td valign=top></td>
                   <td valign=top></td>
               </tr>
               <tr align=center>
                   <td>Tiazofurin<img src="images/Tiazofurin.png" width=130 /></td>
                   <td>Ribavirine<img src="images/Ribavirine.png" width=130 /></td>
                   <td>Mizoribine<img src="images/Mizoribine.png" width=130 /></td>
               </tr>
           </table>
           <!-- End Compounds Table -->
           <span class="FloatRight"><a href="#top" class="ReturnToTop">(^Top)</a></span>
           <br />
           <!-- Bibliography -->
           <table class=small cellSpacing=0 cellPadding=5 align=center>
		       <tr><td valign=top><img src="images/iconsml.gif" width=100/>
                   </td>
			       <td><p><strong>References (with links to PubMed)</strong><br />
                          1. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16919497" class=smallAct target=_blank title="Go to PubMed">L. Hedstrom and L. Gan (2006): IMP dehydrogenase: structural schizophrenia and an unusual base <em>Curr. Opin. Chem. Biol.</em> 10(5), 520-525</a><br />
                          2. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11668509" class=smallAct target=_blank title="Go to PubMed">B. J. Barnes <em>et al.</em> (2001): Mechanism of action of the antitumor agents 6-benzoyl-3,3-disubstituted-1,5-diazabicyclo[3.1.0]hexane-2,4-diones: Potent inhibitors of human type II inosine 5'-monophosphate dehydrogenase <em>Int. J. Cancer.</em> 94(2), 275–281</a><br />
                          3. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16483769" class=smallAct target=_blank title="Go to PubMed">R. E. Beevers <em>et al.</em> (2006): Low molecular weight indole fragments as IMPDH inhibitors <em>Bioorg. Med. Chem. Lett.</em> 16(9), 2535-2538</a><br />
                          4. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17659481" class=smallAct target=_blank title="Go to PubMed">L. Chen and K. W. Pankiewicz (2007): Recent development of IMP dehydrogenase inhibitors for the treatment of cancer <em>Curr. Opin. Drug Discov. Devel.</em> 10(4):403-12 ( Review)</a><br />
                          5. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11454943" class=smallAct target=_blank title="Go to PubMed">B. J. Barnes <em>et al.</em> (2001): Induction of Tmolt4 Leukemia Cell Death by 3,3-Disubstituted-6,6-pentamethylene-1,5-diazabicyclo[3.1.0]hexane-2,4-diones: Specificity for Type II Inosine 5'-Monophosphate Dehydrogenase <em>J. Pharm. Exp. Therap.</em> 298(2), 790-796</a><br />
                          6. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15380335" class=smallAct target=_blank title="Go to PubMed">K. Malek <em>et al.</em> (2004): Effects of the IMP-dehydrogenase inhibitor, Tiazofurin, in bcr-abl positive acute myelogenous leukemia <em>Leukemia Research</em> 28, 1125–1136</a><br />
                          7. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16609701" class=smallAct target=_blank title="Go to PubMed">L. Hong <em>et al.</em> (2006): ZNRD1 mediates resistance of gastric cancer cells to methotrexate by regulation of IMPDH2 and Bcl-2 <em>Biochem. Cell Biol.</em> 84(2): 199–206</a><br />
                          8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15670151" class=smallAct target=_blank title="Go to PubMed">S. Peñuelas <em>et al.</em> (2005): Modulation of IMPDH2, survivin, topoisomerase I and vimentin increases sensitivity to methotrexate in HT29 human colon cancer cells <em>FEBS</em> 272, 696–710</a><br />
                          9. <a href="http://www.ncbi.nlm.nih.gov/pubmed/10097070" class=smallAct target=_blank title="Go to PubMed">T. D. Colby <em>et al.</em> (1999): Crystal structure of human type II inosine monophosphate dehydrogenase: implications for ligand binding and drug design <em>PNAS</em>, 96(7), 3531–3536</a>
                          10. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12781195" class=smallAct target=_blank title="Go to PubMed">E. J. Iwanowicz <em>et al.</em> (2003): Inhibitors of inosine monophosphate dehydrogenase: SARs about the N-[3-Methoxy-4-(5-oxazolyl)phenyl moiety <em>Bioorg. Med. Chem. Lett.</em> 13(12), 2059-2063</a><br />
                          11. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12183689" class=smallAct target=_blank title="Go to PubMed">J. Jain <em>et al.</em> (2002): Characterization of pharmacological efficacy of VX-148, a new potent immunosuppressive inosine 5'-monophosphate dehydrogenase inhibitor <em>J. Pharm. Exp. Therap.</em> 302(3), 1272-1277</a><br />
                          12. <a href="http://www.ncbi.nlm.nih.gov/pubmed/14757177" class=smallAct target=_blank title="Go to PubMed">J. Jain <em>et al.</em> (2004): Regulation of inosine monophosphate dehydrogenase type I and type II isoforms in human lymphocytes <em>Biochem. Pharmacol.</em> 67(4), 767-776</a><br />
                          13. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15664851" class=smallAct target=_blank title="Go to PubMed">G. M. Buckley <em>et al.</em> (2005): Quinazolinethiones and quinazolinediones, novel inhibitors of inosine monophosphate dehydrogenase: synthesis and initial structure–activity relationships <em>Bioorg. Med. Chem. Lett.</em> 15(3), 751-754</a><br />
                          14. <a href="http://www.ncbi.nlm.nih.gov/pubmed/14505670" class=smallAct target=_blank title="Go to PubMed">T. G. Murali Dhar <em>et al.</em> (2003): 3-Cyanoindole-Based Inhibitors of Inosine Monophosphate Dehydrogenase: Synthesis and Initial Structure–Activity Relationships <em>Bioorg. Med. Chem. Lett.</em> 13(20), 3557-3560</a><br />
                       </p>
                   </td>
	           </tr>
           </table>
           <!-- End Bibliography -->
           <div align=right class=medium>Download this document&nbsp;<a href="images/NovoCIB IMPDH target.pdf" target=_blank class="mediumboldRedAct" title="IMPDH, a choice target">"IMPDH - a choice target for major therapeutic applications"&nbsp;<img width=20 src="images/pdficon_large.gif" /></a>
           </div>
       </div>
    </p>
    <!-- End IMPDH, a choice target for major therapeutic applications -->
  </div>  
  
  <br />
  
  <div align="center">
    <table border=1 cellspacing=1 bordercolor=#cc0000>
        <tr align="center" bgcolor="#FFCC00" bordercolor=#ffffff>
            <td colspan="2"><span class="big16boldBlack">Related Links</span>
            </td>
        </tr>
        <tr align="left" valign=top bordercolor=#f5f5f5>
            <td class="RelatedLinksBullet">&bull; <a href="http://www.novocib.com/Bacterial_Recombinant_IMPDH.html" class="defaultAct">Bacterial Recombinant IMPDH</a>
                <br />&bull; <a href="http://www.novocib.com/Recombinant_Purine_Metabolism_Enzymes.html" class="defaultAct">Purine Metabolism Enzymes</a>
                
                
            </td>
            <td class="RelatedLinksBullet">&bull; <a href="http://www.novocib.com/Whole_Cell_Assay_IMPDH_Inhibition.html" class="defaultAct">IMPDH Inhibition: Whole Cell Assay</a>
                
                          
            </td>
        </tr>
    </table>
  </div>
</div>
<!-- End page content -->

<!-- Go to Top of Page -->
<div id="GoToTopOfPage"></div>
<!-- End Go to Top of Page -->

<!-- footer -->
<div id="footer"><br />
<SPAN class="Update">Last Update: 2014/04/18</SPAN><SPAN class="Copyright"> &copy; All Right Reserved | Copyright &reg; NovoCIB | N.Godard 2007 | </SPAN><a href="http://www.novocib.com/Legal_Notice" class="Legal" valign=top title="Legal Notice">Legal Notice</a>
</div>
<!-- End footer -->
</div>


<script type="text/javascript">
    initMenu();
</script>

<script>
  (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
  (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
  m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
  })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

  ga('create', 'UA-47165485-1', 'novocib.com');
  ga('send', 'pageview');

</script>
</body></html>